Photo from Yüksel Ürün/X
Dec 11, 2023, 18:34
Yüksel Ürün: Mirvetuximab Soravtansine (MIRV) shows promise in platinum-resistant ovarian cancer
Yüksel Ürün, Medical Oncologist at Ankara University, shared on X/Twitter:
”Mirvetuximab Soravtansine (MIRV) shows promise in platinum-resistant ovarian cancer! In a recent trial, MIRV led to better survival rates and fewer serious adverse events compared to standard chemo. Personalized treatment could be the future!”
For the article click here.
Source: Yüksel Ürün/X